A Pilot Study of 89Zr-J591 as an Imaging Agent in Patients with Newly Diagnosed Glioblastoma Multiforme

Full Title

A Pilot Study of 89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients with Glioblastoma Multiforme

Purpose

Glioblastoma multiforme is a brain tumor that can be challenging to treat. Doctors are seeking better ways to diagnose and treat this cancer. In this study, researchers are assessing the effectiveness of an imaging agent called 89Zr-J591 in patients with glioblastoma. This drug consists of an antibody called J591 attached to a radioactive substance called zirconium-89. It is being used with positron emission tomography/computed tomography (PET/CT) scanning, which detects the radioactivity of the imaging agent and takes pictures of its location in the brain.

In this study, researchers want to find out how well 89Zr-J591 attaches to the blood vessels feeding the tumor in patients operable glioblastoma. Doctors hope to use this information to improve the imaging and treatment of brain tumors in the future.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have presumed, newly diagnosed, or recurrent grade IV glioblastoma multiforme and be candidates for surgery.
  • This study is open to patients older than age 25 and younger than 80.

For more information about this study and to inquire about eligibility, please contact Dr. Daniel Spratt at 212-639-6531 or Dr. Joseph Osborne at 212-639-7788.

Protocol

15-002

Phase

Pilot

Disease Status

Newly Diagnosed & Relapsed/Refractory

Investigator

Locations